Spyre Therapeutics (FRA:3920) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3920 Spyre Therapeutics Inc FRA:3920
29 GF Score
Price €90.00
GF Value €1.98
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Spyre Therapeutics FFO per Share?

FFO per Share only applies to REITs.

FRA:3920
29GF Score
Spyre Therapeutics Inc FRA:3920
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Spyre Therapeutics (FRA:3920) Overvalued in 2026?

Based on GuruFocus' analysis, Spyre Therapeutics stock appears to be overvalued. The current stock price of €90.00 is trading 4445.5% above its estimated GF Value™ of €1.98. GuruFocus considers Spyre Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:3920:

  • FFO per Share:
  • GF Value™: €1.98 vs. price of €90.00 (4445.5% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the FRA:3920 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spyre Therapeutics Business Description

Other Exchanges SYRE:USA3920:Germany
Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
29GF Score

Get the complete analysis for FRA:3920

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€90.00
Price
€1.98
GF Value